Amgen along with its partner UCB revealed today that their next generation bone treatment, AMG 785/CDP 7851, had met its phase II primary endpoints by significantly increasing bone density at 12 months in 400 postmenupausal women.
AMG 785 is unlike Amgen's current bone drug, denosumab, which blocks bone erosion in patients to help prevent osteoporosis and some cancer-related bone fractures. Denosumab, quite new itself, is expected to generate $3-4 billion. AMG 785 meanwhile blocks sclerosin action and helps a patient build new bone. This is a new approach that may aid patients who have already experienced bone loss.
AMG 785 is now poised to move on to phase III trials. When approved, it would provide Amgen with two options for treatng osteoporosis patients -- an estimated $9 billion market. It is estimated that 20% of women over age 50 in the US have osteoporosis.
Posted by Bruce Lehr April 22nd 2011.